Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab
We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of ida...
Gespeichert in:
| Veröffentlicht in: | BMJ case reports 2019-05, Vol.12 (5), p.e229128 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | e229128 |
| container_title | BMJ case reports |
| container_volume | 12 |
| creator | Loh, Chee Hoou Herkes, Geoffrey |
| description | We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of idarucizumab to reverse of dabigatran is a novel treatment that should be considered as an important adjunct to facilitate thrombolysis for ischaemic strokes and minimise haemorrhagic complications. |
| doi_str_mv | 10.1136/bcr-2018-229128 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6506077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2232134759</sourcerecordid><originalsourceid>FETCH-LOGICAL-b456t-16178744c7b83c7c5cd8ef44c75e934df2873beadeb9499abd68b610392d19203</originalsourceid><addsrcrecordid>eNqFkctrFTEUh0NR2lK77q4E3IgwNo-ZSbIRpNgHFFyo4C4kmTO9uZ2Z1Dyq7V_fXG4t1Y3ZJCHf-XFOPoSOKPlAKe9PrIsNI1Q2jCnK5A7ap6ITjVDkx6sX5z10mNKa1MVpK1u-i_Y4JT2lku2jm6_FOUhpLBPOqxhmG6b75BMeQ8TGlQzYJ7cyMHuHU47hBrAZM0Qc4Q5iMhMOIx6M9dcmR7NgyPDbT6bW_fJ5hf1gYnH-oczGvkGvRzMlOHzaD9D3s8_fTi-aqy_nl6efrhrbdn1uaE-FFG3rhJXcCde5QcK4uXegeDuMTApuwQxgVauUsUMvbU8JV2ygihF-gD5uc2-LnWFwsNTOJn0b_WzivQ7G679fFr_S1-FO9x3piRA14N1TQAw_C6Ss5_oJME1mgVCSZowzylvRqYq-_QddhxKXOl6lqhxa1chKnWwpF0NKEcbnZijRG5e6utQbl3rrslYcv5zhmf9jrgLvt4Cd1_9NewR8Zqnv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2220112918</pqid></control><display><type>article</type><title>Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Loh, Chee Hoou ; Herkes, Geoffrey</creator><creatorcontrib>Loh, Chee Hoou ; Herkes, Geoffrey</creatorcontrib><description>We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of idarucizumab to reverse of dabigatran is a novel treatment that should be considered as an important adjunct to facilitate thrombolysis for ischaemic strokes and minimise haemorrhagic complications.</description><identifier>ISSN: 1757-790X</identifier><identifier>EISSN: 1757-790X</identifier><identifier>DOI: 10.1136/bcr-2018-229128</identifier><identifier>PMID: 31061182</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Aged ; Antibodies, Monoclonal, Humanized - administration & dosage ; Anticoagulants ; Blood clots ; Brain Ischemia - diagnostic imaging ; Brain Ischemia - drug therapy ; Brain Ischemia - pathology ; Cardiac arrhythmia ; Cardiomyopathy ; Case reports ; Dabigatran - adverse effects ; Heart attacks ; Humans ; Male ; Monoclonal antibodies ; Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) ; Patients ; Stroke ; Stroke - diagnostic imaging ; Stroke - drug therapy ; Stroke - pathology ; Thrombolytic Therapy - adverse effects ; Tomography, X-Ray Computed ; Treatment Outcome</subject><ispartof>BMJ case reports, 2019-05, Vol.12 (5), p.e229128</ispartof><rights>BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2019 BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b456t-16178744c7b83c7c5cd8ef44c75e934df2873beadeb9499abd68b610392d19203</citedby><cites>FETCH-LOGICAL-b456t-16178744c7b83c7c5cd8ef44c75e934df2873beadeb9499abd68b610392d19203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506077/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506077/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31061182$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Loh, Chee Hoou</creatorcontrib><creatorcontrib>Herkes, Geoffrey</creatorcontrib><title>Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab</title><title>BMJ case reports</title><addtitle>BMJ Case Rep</addtitle><description>We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of idarucizumab to reverse of dabigatran is a novel treatment that should be considered as an important adjunct to facilitate thrombolysis for ischaemic strokes and minimise haemorrhagic complications.</description><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Anticoagulants</subject><subject>Blood clots</subject><subject>Brain Ischemia - diagnostic imaging</subject><subject>Brain Ischemia - drug therapy</subject><subject>Brain Ischemia - pathology</subject><subject>Cardiac arrhythmia</subject><subject>Cardiomyopathy</subject><subject>Case reports</subject><subject>Dabigatran - adverse effects</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Male</subject><subject>Monoclonal antibodies</subject><subject>Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)</subject><subject>Patients</subject><subject>Stroke</subject><subject>Stroke - diagnostic imaging</subject><subject>Stroke - drug therapy</subject><subject>Stroke - pathology</subject><subject>Thrombolytic Therapy - adverse effects</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><issn>1757-790X</issn><issn>1757-790X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkctrFTEUh0NR2lK77q4E3IgwNo-ZSbIRpNgHFFyo4C4kmTO9uZ2Z1Dyq7V_fXG4t1Y3ZJCHf-XFOPoSOKPlAKe9PrIsNI1Q2jCnK5A7ap6ITjVDkx6sX5z10mNKa1MVpK1u-i_Y4JT2lku2jm6_FOUhpLBPOqxhmG6b75BMeQ8TGlQzYJ7cyMHuHU47hBrAZM0Qc4Q5iMhMOIx6M9dcmR7NgyPDbT6bW_fJ5hf1gYnH-oczGvkGvRzMlOHzaD9D3s8_fTi-aqy_nl6efrhrbdn1uaE-FFG3rhJXcCde5QcK4uXegeDuMTApuwQxgVauUsUMvbU8JV2ygihF-gD5uc2-LnWFwsNTOJn0b_WzivQ7G679fFr_S1-FO9x3piRA14N1TQAw_C6Ss5_oJME1mgVCSZowzylvRqYq-_QddhxKXOl6lqhxa1chKnWwpF0NKEcbnZijRG5e6utQbl3rrslYcv5zhmf9jrgLvt4Cd1_9NewR8Zqnv</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Loh, Chee Hoou</creator><creator>Herkes, Geoffrey</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190501</creationdate><title>Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab</title><author>Loh, Chee Hoou ; Herkes, Geoffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b456t-16178744c7b83c7c5cd8ef44c75e934df2873beadeb9499abd68b610392d19203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Anticoagulants</topic><topic>Blood clots</topic><topic>Brain Ischemia - diagnostic imaging</topic><topic>Brain Ischemia - drug therapy</topic><topic>Brain Ischemia - pathology</topic><topic>Cardiac arrhythmia</topic><topic>Cardiomyopathy</topic><topic>Case reports</topic><topic>Dabigatran - adverse effects</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Male</topic><topic>Monoclonal antibodies</topic><topic>Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)</topic><topic>Patients</topic><topic>Stroke</topic><topic>Stroke - diagnostic imaging</topic><topic>Stroke - drug therapy</topic><topic>Stroke - pathology</topic><topic>Thrombolytic Therapy - adverse effects</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Loh, Chee Hoou</creatorcontrib><creatorcontrib>Herkes, Geoffrey</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loh, Chee Hoou</au><au>Herkes, Geoffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab</atitle><jtitle>BMJ case reports</jtitle><addtitle>BMJ Case Rep</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>12</volume><issue>5</issue><spage>e229128</spage><pages>e229128-</pages><issn>1757-790X</issn><eissn>1757-790X</eissn><abstract>We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of idarucizumab to reverse of dabigatran is a novel treatment that should be considered as an important adjunct to facilitate thrombolysis for ischaemic strokes and minimise haemorrhagic complications.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>31061182</pmid><doi>10.1136/bcr-2018-229128</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1757-790X |
| ispartof | BMJ case reports, 2019-05, Vol.12 (5), p.e229128 |
| issn | 1757-790X 1757-790X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6506077 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Aged Antibodies, Monoclonal, Humanized - administration & dosage Anticoagulants Blood clots Brain Ischemia - diagnostic imaging Brain Ischemia - drug therapy Brain Ischemia - pathology Cardiac arrhythmia Cardiomyopathy Case reports Dabigatran - adverse effects Heart attacks Humans Male Monoclonal antibodies Novel Treatment (New Drug/Intervention Established Drug/Procedure in New Situation) Patients Stroke Stroke - diagnostic imaging Stroke - drug therapy Stroke - pathology Thrombolytic Therapy - adverse effects Tomography, X-Ray Computed Treatment Outcome |
| title | Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A21%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20thrombolysis%20for%20acute%20ischaemic%20stroke%20after%20reversal%20of%20dabigatran%20etexilate%20with%20idarucizumab&rft.jtitle=BMJ%20case%20reports&rft.au=Loh,%20Chee%20Hoou&rft.date=2019-05-01&rft.volume=12&rft.issue=5&rft.spage=e229128&rft.pages=e229128-&rft.issn=1757-790X&rft.eissn=1757-790X&rft_id=info:doi/10.1136/bcr-2018-229128&rft_dat=%3Cproquest_pubme%3E2232134759%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2220112918&rft_id=info:pmid/31061182&rfr_iscdi=true |